The Fly | XFOR

First-in-Class Approved Therapy for WHIM: Mavorixafor is the first and only FDA-approved therapy for WHIM syndrome, establishing a significant market lead and direct access to an underserved patient population.

Orphan Drug Exclusivity Protection: Mavorixafor benefits from Orphan Drug Designation, granting statutory marketing exclusivity for WHIM syndrome and providing a competitive barrier to entry for potential rivals.

Addressing Significant Unmet Medical Need: WHIM syndrome is a rare, chronic immunodeficiency with no prior approved treatments, positioning X4 as the sole provider of a critical therapeutic option.

Clinical Trial Failure and Regulatory Delay: Motixafortide's development for additional indications, such as WHIM syndrome, faces inherent risks of clinical trial failure, unexpected adverse events, or significant delays, which could prevent regulatory approval or extend development timelines.

Aphexda Commercialization and Market Adoption Challenges: Despite its approval for stem cell mobilization in multiple myeloma, Aphexda's commercial success depends on achieving significant market adoption, securing favorable reimbursement, and overcoming potential competition, which may not meet investor expectations.

Capital Needs and Share Dilution Risk: X4 Pharmaceuticals is a pre-profit company with significant cash burn, requiring substantial additional capital to fund ongoing research, clinical trials, and commercialization efforts, which will likely lead to future equity offerings and dilution for existing shareholders.

Charts

Addressing Significant Unmet Medical Need: WHIM syndrome is a rare, chronic immunodeficiency with no prior approved treatments, positioning X4 as the sole provider of a critical therapeutic option.